Tianjin Pharmaceutical da Ren Tang Group Ltd 2025 AR2
The 2025 Annual Report of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited highlights the company's financial performance, operational achievements, and strategic transition to a premium traditional Chinese medicine focus. Key developments include advancements in intelligent manufacturing, R&D innovation, and brand revitalization. The report also briefly addresses the company's commitment to sustainability, product quality, and social responsibility, noting that a dedicated task force monitors its ESG performance.
Company: Tianjin Pharmaceutical da Ren Tang Group Ltd
Sector: Manufacturing
Country: China
Year: 2025
Type: AR2
Pages: 206
Back to company
Tianjin Pharmaceutical da Ren Tang Group Ltd
Annual Report
The 2025 Annual Report of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited highlights the company's financial performance, operational achievements, and strategic transition to a premium traditional Chinese medicine focus. Key developments include advancements in intelligent manufacturing, R&D innovation, and brand revitalization. The report also briefly addresses the company's commitment to sustainability, product quality, and social responsibility, noting that a dedicated task force monitors its ESG performance.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
No data available